Institute for Systems Biology
VC Fund
Seattle, United States
Institute for Systems Biology is a non-profit biomedical research organization based in Washington. It concentrates on systems biology, the study of relationships and interactions between various parts of biological systems, and advocates an interdisciplinary approach to biological research. The company’s research aids scientists to develop cures,treatments, and preventive measures for cancers, diseases, and environmental ills.Institute for Systems Biology was founded in 2000 and is based in Seattle, Washington.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Institute for Systems Biology invests in
BankingFinanceMedicalHealth CareTherapeutics
Stages Institute for Systems Biology invests in
Series AFunding Round
Countries Institute for Systems Biology invests in
United States
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Banking 1 (33%)
- Finance 1 (33%)
- Medical 1 (33%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
Stage
- Series A 1 (33%)
- Funding Round 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alan Aderem
Affiliate Faculty
|
Affiliate Faculty | Total investments: 0 | Find email | |
Jennifer Lovejoy
Affiliate Faculty
|
Affiliate Faculty | Total investments: 0 | Find email | |
Kathy Scanlan
Chief Operating Officer & Treasurer
|
Chief Operating Officer & Treasurer | Total investments: 0 | Find email | |
Nathan Price
Professor
|
Professor | Total investments: 0 | Find email | |
Nitin Baliga
Senior Vice President & Director; Professor
|
Senior Vice President & Director; Professor | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Theraclone Sciences
|
Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cellsof immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment. | $4.6M / Series A / Mar 03, 2006 | |
Accelerator Corp.
|
Accelerator Corporation is a venture capital firm specializing in incubation, early stage, emerging growth and start-up investments. It does not participate in further rounds of financing. The firm prefers to invest in biotechnology companies. It seeks to invest up to $2 million in a company. The firm typically holds its investments for a period of12 months to 24 months. Accelerator Corporation was founded in 2003 and is based in Seattle, Washington.Accelerator Corporation, founded in 2003, is a vehicle for disciplined and efficient investment in and management of emerging biotechnology opportunities. Located in Seattle, Washington, the company identifies, evaluates, finances, and manages ground breaking emerging life sciences opportunities. The company has established and built a largely proprietary array of sources of deal flow, as well as a key set of resources to bring to bear in the development of the best opportunities emerging from those sources. These key resources, provided by Accelerator and its Affiliates – Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, WRF Capital, Alexandria Real Estate Equities, Inc., and the Institute for Systems Biology – include committed investment capital, state-of-the-art facilities, world-class scientific and technical expertise and support, and experienced start-up management. This panel of Accelerator participants will discuss the success of their business model and provide practical expertise for the next generation of biotech incubators.In the past five years, nine companies have been invested in through Accelerator. Three have emerged and raised follow on financings of more than $114 million. Four remain under management at Accelerator, having raised between them $11.3 million in initial Accelerator-based investments. In all, Accelerator companies have raised in excess of $143.5 million in initial and follow-on financings.Accelerator investors have committed an additional $22.5 million to enable Accelerator to continue to identify, capitalize, and develop the next-generation of exciting emerging biotechnologies. Accelerator Corporation relies upon a unique set of sources to fill a world-class pipeline of deal flow and has established and utilized a now proven array of resources to identify, evaluate, capitalize and manage emerging biotechnology companies. Accelerator provides this unprecedented collection of resources via a partnership between top-tiered investors, dedicated management, and a world-class research institute. These groups have come together because they recognize the potential of biotechnology both as an investment opportunity and as a critical component of the rapidly evolving future of medicine and healthcare. Moreover, these individuals and organizations have extensive experience in the difficult, complex and costly process of transforming an exciting laboratory discovery into a commercial product. By providing their expertise with companies in the Accelerator portfolio, these industry leaders provide critical knowledge and resources that can help to streamline the development and accelerate the commercialization of novel technologies.Accelerator, through the global activities of its affiliates, has access to exciting new technologies and commercial opportunities developed at leading research institutions, universities and biotechnology companies around the world. This enables Accelerator to select only the most compelling investments from a deep pool of promising opportunities. | $11.8M / Nov 19, 2004 | |
|
Accelerator Corp.
|
Accelerator Corporation is a venture capital firm specializing in incubation, early stage, emerging growth and start-up investments. It does not participate in further rounds of financing. The firm prefers to invest in biotechnology companies. It seeks to invest up to $2 million in a company. The firm typically holds its investments for a period of12 months to 24 months. Accelerator Corporation was founded in 2003 and is based in Seattle, Washington.Accelerator Corporation, founded in 2003, is a vehicle for disciplined and efficient investment in and management of emerging biotechnology opportunities. Located in Seattle, Washington, the company identifies, evaluates, finances, and manages ground breaking emerging life sciences opportunities. The company has established and built a largely proprietary array of sources of deal flow, as well as a key set of resources to bring to bear in the development of the best opportunities emerging from those sources. These key resources, provided by Accelerator and its Affiliates – Amgen Ventures, ARCH Venture Partners, OVP Venture Partners, WRF Capital, Alexandria Real Estate Equities, Inc., and the Institute for Systems Biology – include committed investment capital, state-of-the-art facilities, world-class scientific and technical expertise and support, and experienced start-up management. This panel of Accelerator participants will discuss the success of their business model and provide practical expertise for the next generation of biotech incubators.In the past five years, nine companies have been invested in through Accelerator. Three have emerged and raised follow on financings of more than $114 million. Four remain under management at Accelerator, having raised between them $11.3 million in initial Accelerator-based investments. In all, Accelerator companies have raised in excess of $143.5 million in initial and follow-on financings.Accelerator investors have committed an additional $22.5 million to enable Accelerator to continue to identify, capitalize, and develop the next-generation of exciting emerging biotechnologies. Accelerator Corporation relies upon a unique set of sources to fill a world-class pipeline of deal flow and has established and utilized a now proven array of resources to identify, evaluate, capitalize and manage emerging biotechnology companies. Accelerator provides this unprecedented collection of resources via a partnership between top-tiered investors, dedicated management, and a world-class research institute. These groups have come together because they recognize the potential of biotechnology both as an investment opportunity and as a critical component of the rapidly evolving future of medicine and healthcare. Moreover, these individuals and organizations have extensive experience in the difficult, complex and costly process of transforming an exciting laboratory discovery into a commercial product. By providing their expertise with companies in the Accelerator portfolio, these industry leaders provide critical knowledge and resources that can help to streamline the development and accelerate the commercialization of novel technologies.Accelerator, through the global activities of its affiliates, has access to exciting new technologies and commercial opportunities developed at leading research institutions, universities and biotechnology companies around the world. This enables Accelerator to select only the most compelling investments from a deep pool of promising opportunities. | $15M / May 22, 2003 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FinTech Investors
43,106 investors
Health Care Investors
43,014 investors
Medical Investors
18,848 investors
Finance Investors
15,513 investors
FinTech VC Funds
28,664 investors
Health Care VC Funds
32,370 investors
Medical VC Funds
16,214 investors
Finance VC Funds
11,563 investors
FinTech Investors in United States
19,839 investors
FAQ
What does Institute for Systems Biology invest in?
Institute for Systems Biology invests primarily in Banking, Finance and Medical startups, most often at Series A and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Institute for Systems Biology?
Public channels for Institute for Systems Biology include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Institute for Systems Biology?
The team at Institute for Systems Biology includes Alan Aderem (Affiliate Faculty), Jennifer Lovejoy (Affiliate Faculty) and Kathy Scanlan (Chief Operating Officer & Treasurer), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
